|MDACC Study No:||2009-0625 (clinicaltrials.gov NCT No: NCT01193517)|
|Title:||Phase I/II Study of Azacitidine and CAPOX (Capecitabine + Oxaliplatin) in Metastatic Colorectal Cancer Patients Enriched for Hypermethylation of CpG Promoter Islands|
|Principal Investigator:||Michael Overman|
|Treatment Agent:||Azacitidine; Capecitabine; Oxaliplatin|
|Study Description:||The goal of the Phase I portion of this study is to find the highest tolerable |
dose of azacitidine combined with capecitabine and oxaliplatin (CAPOX) that can
be given to patients with metastatic colorectal cancer.
The goal of the Phase II portion of this study is to learn if azacitidine,
given in combination with CAPOX, can help to control metastatic colorectal
cancer. The safety of this drug combination will also be studied.